MBX Capital | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/MBX Capital/Activity

MBX Capital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Participated in Keebler Health's $16M Series A for LLM-native risk adjustment and population health infrastructure.

Keebler Health

Keebler Health MBX Capital

businesswire.comAPR 15, 2026

thesaasnews.com

APR 15, 2026

Exit

Portfolio company CareRev was acquired by IntelyCare to combine acute and post-acute healthcare workforce staffing platforms.

CareRev

CareRev MBX Capital

carerev.comJAN 8, 2026

forgeglobal.com

JAN 8, 2026

Investment

Participated in Think Bioscience's $55M oversubscribed Series A for synthetic biology drug discovery.

Think Bioscience

Think Bioscience MBX Capital

prnewswire.comJAN 2026

JAN 2026

News

Crossed $100M+ in cumulative capital commitments with sharpened thesis focused on environmental toxins and chronic disease prevention.

$100M+ cumulative commitments and environmental toxins thesis focus

hitconsultant.netDEC 2025

DEC 2025

Investment

Participated as existing investor in Vivodyne's $40M Series A for AI-powered human tissue testing replacing animal models.

Vivodyne

Vivodyne MBX Capital

finsmes.comMAY 2025

MAY 2025

Investment

Participated in Persist AI's Series A for cloud-based pharmaceutical formulation screening using AI and robotics.

Persist AI

Persist AI MBX Capital

builtincolorado.comMAY 2025

MAY 2025